Using plasma glutathione S-transferase measurements hepatocellular integrity was assessed in groups of hyperthyroid and hypothyroid patients before and after treatment.
Introduction
Before the advent of effective treatment for hyperthyroidism serious hepatobiliary complications were commonly associated with the disease. Liver biopsy samples taken from hyperthyroid patients often showed morphological changes which included glycogen depletion, fatty change, and cirrhosis. These associated hepatic problems have been attributed to many factors, including cardiac failure, infection, hypoxia, and malnutrition, and are not thought to be due to a direct effect of thyroid hormones on the liver. ' Prolonged and severe hyperthyroidism now occurs only occasionally and, as a consequence, severe hepatobiliary dysfunction associated with hyperthyroidism is rare. There is, however, evidence that hyperthyroidism may still produce associated minor hepatic abnormalities, and electron microscopy of liver biopsy samples shows non-specific changes in the hepatocyte organelles.' Biochemical evidence of hepatic dysfunction may still be seen in some patients with hyperthyroidism. In one study retention of sulphobromophthalein was abnormal in 8°0 of patients, and abnormalities in bilirubin and alanine aminotransferase values also were observed, but less frequently. 3 There is little evidence to suggest that hypothyroidism affects liver function, but these patients will subsequently receive levothyroxine replacement therapy. As a result many will have raised plasma total and free thyroxine (T4) concentrations with normal total and free triiodothyronine (T3) concentrations. 4 Of particular interest is the question whether these patients, who appear euthyroid clinically, have tissue hyperthyroidism.5 Measurement of the changes which occur in cardiac and pituitary response in these patients suggests that tissue hyperthyroidism does result from this treatment. 5 Nevertheless, thyroxine replacement therapy has not been shown to have a detrimental effect on hepatic function.
The measurement of plasma glutathione S-transferase by radioimmunoassay offers an extremely sensitive method of investigating hepatocellular damage, both in animals and man.6-9 These measurements are non-invasive and the results correlate well with the histological findings in the liver.-In drug induced liver damage plasma glutathione S-transferase measurements appear to be some 10 times more sensitive at detecting damage than measurements of aminotransferase activities. ' We report the use of plasma glutathione S-transferase measurements and standard chemical tests of liver function to investigate the hepatocellular integrity of patients with thyroid diseases. We have also examined the effect of thyroxine replacement on hepatocellular integrity in hypothyroid patients.
Patients and methods

HYPERTHYROID PATIENTS
We studied two groups of patients with hyperthyroidism. The first group consisted of five women aged 46-75 years (cases 1-5; see table I) who were treated with iodine-131. All had raised plasma concentrations of total T4 and total T3 at presentation, and all showed a basally suppressed thyroid stimulating hormone concentration which did not rise by more than 1 mU/l 20 minutes after an intravenous injection of 200 jig thyrotrophin releasing hormone.
The second group consisted of nine younger women (aged 19-45 years; cases [6] [7] [8] [9] [10] [11] [12] [13] [14] in whom a study had been undertaken to assess the merits of different treatment schedules with carbimazole. These schedules were (a) 15 mg carbimazole three times a day for one month, subsequently reduced in the light of clinical and biochemical response, and (b) administration of a continuous blocking dose of 15 mg carbimazole three times a day with triiodothyronine replacement (20 jug thrice daily) being added after roughly one month to prevent hypothyroidism. As in the first group, all patients had raised total T4 and total T3 concentrations at presentation with a lack of response of thyroid stimulating hormone to injection of thyrotrophin releasing hormone.
In all patients blood was taken at presentation and plasma stored at -20°C for the subsequent measurement of total and free T4 values, total and free T3, glutathione S-transferase, aspartate aminotransferase, y-glutamyltransferase, and alkaline phosphatase. In the first group of patients a second sample was taken when they had been rendered euthyroid. In the patients treated with carbimazole more frequent sampling was employed. 
MEASUREMENTS
Concentrations of total T4 and total T3 were measured by radioimmunoassay using a double antibody system.'0 Free T4 and free T3 concentrations were measured with commercial kits (Amersham International PLC). Reference ranges derived from 98 clinically and biochemically euthyroid patients were: total T4, 65-145 nmol/l (5-1-11-3 ,ug/100 ml); total T3, 1-2-2-8 nmol/l (0-8-1-8 ng/ml); free T4, 10-22 pmol/l (7-8-17-1 pg/ml); free T3, 4-0-7-8 pmol/l (2-6-5-1 pg/ml).
Plasma glutathione S-transferase was measured by radioimmunoassay." The concentration of hepatic glutathione S-transferase B,B55' (previously referred to as basic glutathione S-transferase')
was measured with a specific antiserum which showed no cross reactivity with the anionic forms of glutathione S-transferase found in red cells, muscle, or lung. The upper limit of the reference range for glutathione S-transferase B5B, was 4-0 iLg/l and was derived from 135 blood donors and 40 laboratory volunteers.
The activities of aLkaline phosphatase and y-glutamyltransferase in plasma were measured by a sequential multiple analysis with computer system (SMAC II, Technicon Instrument Corporation, Basingstoke). The activity of aspartate aminotransferase was measured with a centrifugal fast analyser and a kit method (Merckotest A, E Merck, Darmstadt).
The between and within batch coefficient of variation was <9% for each assay.
Statistical analysis was by Wilcoxon's matched pairs test.
Results
HYPERTHYROID PATIENTS GIVEN 3'I1
Three of the five patients treated with 1311 initially had raised plasma glutathione S-transferase values. After treatment all showed a significant (p <0-05) fall in values to within the reference range 1) . In one patient (case 1) the glutathione S-transferase value was at the upper limit of the reference range after treatment, but in this patient the 131I had produced hypothyroidism necessitating thyroxine replacement therapy. Table I gives the results of the standard liver function tests. The three patients in whom glutathione S-transferase was raised also showed abnormalities in aspartate aminotransferase, alkaline phosphatase, and y-glutamyltransferase activities. In addition, one further patient had an isolated increase in alkaline phosphatase 10- activity. Patients did not show a significant fall in aspartate aminotransferase or alkaline phosphatase after treatment, but y-glutamyltransferase activities did fall significantly (p < 0-05) with treatment.
HYPERTHYROID PATIENTS GIVEN CARBIMAZOLE
All patients treated with carbimazole initially had raised plasma glutathione S-transferase values. After treatment all showed a significant (p <0-01) fall in values. Although the fall in plasma glutathione S-transferase tended to parallel the fall in total and free T4 concentrations, equivocal or raised glutathione S-transferase values were still found up to five months after the start of treatment (fig 2) . No significant difference in glutathione S-transferase values after treatment were observed between the different carbimazole treatment regimens.
In several patients there was a transient rise in glutathione Stransferase after the initiation of treatment (fig 2) . In one (case 14), who showed a sensitivity reaction of a skin rash and arthralgia, the rise was pronounced. In this patient subsequent treatment with propylthiouracil produced a similar rise in glutathione S-transferase with a concomitant sensitivity reaction (fig 3) . In this patient treatment was subsequently changed to 1311.
Although glutathione S-transferase values were raised in all patients before treatment, only four showed abnormalities in standard liver function values ( (table II) .
After thyroxine replacement therapy all patients showed a significant (p < 0 01) rise in plasma glutathione S-transferase (fig 4) . In four patients clearly raised values were found, similar to those observed in the hyperthyroid patients. During thyroxine replacement three patients had raised free T4 concentrations, and in each of these raised glutathione S-transferase values were found. The patient in whom free T4 was normal and glutathione S-transferase raised had been receiving long term treatment with mefenamic acid. This patient also showed abnormalities in aspartate aminotransferase and alkaline phosphatase activities after treatment with thyroxine. In all other patients normal free T4, total T4, and glutathione S-transferase values were found after treatment. All eight patients had normal concentrations of free and total T3 and either normal or suppressed concentrations of thyroid stimulating hormone. There appeared to be no association between glutathione S-transferase values after treatment and the dose or duration of thyroxine replacement therapy.
After thyroxine replacement therapy there was a significant (p < 0-05) increase in alkaline phosphatase activity (table I). Two of the patients with raised free T4 concentrations after treatment had abnormalities in y-glutamyltransferase, and in one of these patients aspartate aminotransferase activity was also increased. Unlike aspartate aminotransferase, plasma glutathione Stransferase values appear to correlate well with the histological picture in patients with chronic active liver disease,7 and also unlike alanine aminotransferase the incidence of abnormal glutathione S-transferase values in patients with paracetamol poisoning8 agrees well with the incidence of abnormal histological findings in the livers of these patients.13 In this context our finding of a high incidence of raised plasma glutathione S-transferase values in hyperthyroidism agrees with the previously reported observation, with electron microscopy, that minor structural abnormalities commonly occur in the organelles of the hepatocytes of patients with this disease.2 Our observations are therefore consistent with the hypothesis that minor hepatocellular dysfunction may still be a common though subclinical complication in hyperthyroidism.
Glutathione S-transferases are a "multigene" group of enzymes that are concerned in the cellular detoxification of a wide range of electrophiles. In human liver and kidney the main forms of the enzymes are cationic (pI 8-4-8-9), while in other tissues an anionic form (pI 4 8) predominates. These enzymes are dimeric, and in human liver two cationic subunits, B1 and B2, have been identified. The radioimmunoassays which we use are specific for either the B1 or B2 monomers and do not react with the anionic forms of glutathione Stransferase. As well as the plasma values of hepatic glutathione S-transferase B1Bj we also measured hepatic glutathione S-transferase B2B2 (previously called N/A2b).1' 12 For clarity these data have not been included but in all cases abnormal basic glutathione S-transferase B1Bj values were associated with abnormal values of glutathione S-transferase B2B2. The subunit forms of glutathione S-transferase which we have measured specifically by radioimmunoassay are confined predominantly to the hepatocyte and the renal tubules, little of these subunit forms being found in tissues such as muscle, red cells, or lung. 14 We have considered the possibilities that the raised plasma glutathione S-transferase values found in the hyperthyroid patients were a consequence of hepatic enzyme induction by thyroxine or may merely have reflected extrahepatic tissue damage. Both these possibilities seem unlikely. Firstly, when thyroxine is administered to hypothyroid or euthyroid animals either a small decrease or no change in hepatic glutathione S-transferase is observed.15 Secondly, as the cationic forms of glutathione S-transferase are relatively specific to the liver and kidney, and since renal damage is not found in hyperthyroidism, it appears that the abnormal plasma values of both B, and B, originate from hepatic damage.
The cause of the hepatic lesions observed in hyperthyroidism is not clear but is believed to be multifactorial, with selective and general hypoxia as contributory factors.' Thyroxine itself has not been reported as directly hepatotoxic. Nevertheless, our observation that prolonged administration of thyroxine to hypothyroid patients resulted in significant increases in plasma glutathione S-transferase in all patients has implications for the long term management of these patients. It is also relevant to the controversy about the importance of raised plasma free T4 concentrations in patients receiving thyroxine.
In our study all of the treated hypothyroid patients with raised free T4 concentrations had associated abnormalities in plasma glutathione S-transferase values. Our data may indicate that administration of thyroxine in doses which result in raised plasma concentrations of free T4 may produce a hepatic lesion similar to that seen in hyperthyroidism. Jennings et al have shown that hypothyroid patients who are receiving thyroxine replacement and in whom free and total T4 concentrations are raised have a decreased systolic time interval, which suggests that they have a "tissue thyrotoxicosis."' Our data suggest that they may also have a "liver thyrotoxicosis."
The thyroid gland secretes approximately 90 ,ug thyroxine a day into the peripheral circulation. Patients who are receiving oral replacement therapy will receive roughly this amount as a single dose. Administered in this way, high concentrations of thyroxine are presented to the liver, through the portal vein. Thus, although peripheral blood concentrations of thyroid hormone may appear satisfactory, it is possible that in these patients liver thyrotoxicosis results from an exposure to high portal concentrations of thyroxine.
Plasma glutathione S-transferase values returned to normal in hyperthyroid patients treated with "3'I, but in patients treated with carbimazole they remained raised even five months after treatment began. In roughly half of the carbimazole treated patients glutathione S-transferase values were increased in the first sample after treatment; in one patient this rise was pronounced and associated with physical signs of a sensitivity reaction. It appears that carbimazole may cause transient subclinical liver damage in some patients, and hepatobiliary problems associated with carbimazole, methimazole, and propylthiouracil have been reported in a few.'6-18 Our data, however, do not show that carbimazole is necessarily hazardous, since the rises in plasma glutathione S-transferase after carbimazole were transient and patients are unlikely to receive carbimazole for long periods. On the other hand, our finding that hepatic abnormalities may occur in patients receiving thyroxine replacement is of concern, since for these patients treatment will be life long. Hepatic function should therefore be considered and assessed periodically in such patients. Measurement of the plasma glutathione S-transferase value by radioimmunoassay appears to provide the most sensitive and specific method of assessing hepatic function in these patients. Nevertheless, the availability of glutathione S-transferase assays is restricted to a few centres, and it is therefore reassuring to note that three of the four hypothyroid patients who had raised glutathione S-transferase values after treatment would have been detected by the standard liver function tests. These tests may offer a satisfactory alternative to glutathione S-transferase measurements in clinical practice.
In conclusion, our data, and those of others,5 indicate that the thyroxine dose should be lowered in patients who have raised free thyroid hormone concentrations in order that free T3 and free T4 may revert to normal.
